Syncom Formulations confirms non-applicability of SEBI Large Corporate criteria
Syncom Formulations (India) Limited confirmed to BSE and NSE on April 3, 2026, that it does not qualify as a "Large Corporate" under SEBI regulations. This classification exempts the WHO-GMP and ISO 9001-2000 certified pharmaceutical company from submitting Annual Disclosure requirements in Annexure B2 for the financial year ended March 31, 2026. The confirmation references multiple SEBI circulars and was digitally signed by Company Secretary Vaishali Agrawal for regulatory compliance and investor transparency.
*this image is generated using AI for illustrative purposes only.
Syncom formulations (India) Limited has officially notified BSE and NSE that it does not fall under the category of "Large Corporate" as defined by SEBI regulations. The WHO-GMP and ISO 9001-2000 certified pharmaceutical company submitted this confirmation on April 3, 2026, ensuring compliance with regulatory disclosure requirements.
Regulatory Framework and Compliance
The company's confirmation references multiple SEBI circulars that define Large Corporate criteria. The primary regulation cited is SEBI Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, which was subsequently updated on April 13, 2022. Additional regulatory guidance comes from SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, along with BSE Notice No. 20220427-2 dated April 27, 2022.
| Regulatory Reference: | Details |
|---|---|
| Primary SEBI Circular: | SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021 |
| Update Date: | April 13, 2022 |
| Additional Circular: | SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023 |
| BSE Notice: | 20220427-2 dated April 27, 2022 |
| Financial Year: | Ended March 31, 2026 |
Exemption from Annual Disclosure Requirements
By confirming its non-Large Corporate status, Syncom Formulations is exempt from submitting the Annual Disclosure in Annexure B2 for the financial year ended March 31, 2026. This exemption reduces the company's regulatory compliance burden while maintaining transparency with investors and stakeholders.
Corporate Communication and Filing
The confirmation was digitally signed by Vaishali Agrawal, Company Secretary and Compliance Officer, on April 3, 2026. The document was filed online through the official portals of both stock exchanges - www.listing.bseindia.com for BSE and the NEAPS portal for NSE. The company has requested both exchanges to disseminate this information on their websites for investor awareness.
Company Profile
Syncom Formulations operates as a WHO-GMP and ISO 9001-2000 certified pharmaceutical company with CIN No. L24239MH1988PLC047759. The company maintains multiple operational locations including its registered office in Mumbai, manufacturing works in Pithampur, Madhya Pradesh, and corporate office in Indore. The company trades on BSE under code 524470 and on NSE under the symbol SYNCOMF.
Historical Stock Returns for Syncom Formulations
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.89% | +1.56% | -4.63% | -28.46% | -31.35% | +44.94% |
What are the specific financial thresholds that determine Large Corporate status, and how close is Syncom to potentially crossing them in future years?
How might this non-Large Corporate status impact Syncom's ability to raise capital or attract institutional investors compared to larger pharmaceutical peers?
Will Syncom's reduced compliance burden translate into cost savings that could improve profitability or fund R&D investments?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
